Thursday, August 18, 2022: Life Sciences

The Food and Drug Administration (FDA) approved Bluebird Bio Inc.’s Zynteglo gene therapy. The approval gives patients suffering from a rare genetic blood disorder called beta-thalassemia a possible cure, at a hefty price. Bluebird, which has priced the...

Thursday, August 18, 2022: Payers

J.D. Power’s annual study of Medicare Advantage (MA) plans found that members are satisfied with the plans, but say mental health and substance use disorder (SUD) treatment coverage is lacking. Ninety-one percent members said they have enough coverage for...